3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
1
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Rectal Neoplasms
3
Stomach Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Skin Neoplasms
1
Sarcoma, Ewing
1
Radiation Injuries
1
Postoperative Complications
1
Pilonidal Sinus
1
Osteosarcoma
1
Neoplasms
1
Lymphatic Metastasis
1
Low Anterior Resection Syndrome
1
Gestational Trophoblastic Disease
1
Fatigue
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Cisplatin
2
ponatinib
1
pembrolizumab
1
Surgical Procedures, Operative
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Platinum
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Induction Chemotherapy
1
Hydroxyurea
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Erlotinib Hydrochloride
1
Biopsy
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma, Squamous Cell
×
Surgical Procedures, Operative
×
Clear all
NCT06295809
2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
46 enrolled